Mechanism of Protein Synthesis and Translational Control
蛋白质合成与翻译控制机制
基本信息
- 批准号:10414150
- 负责人:
- 金额:$ 35.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AmericanAntiviral AgentsBindingBiochemicalBrainCellsCellular StressCessation of lifeChildhoodCodeComplexConserved SequenceDataDevelopmentDiseaseDrug TargetingEukaryotic Initiation Factor-4EFMR1FXR1 geneFXR2 geneFragile X SyndromeGene SilencingGenesGoalsIn VitroInfluenza A virusIntellectual functioning disabilityKnowledgeMammalsMessenger RNAMolecularPatientsPersonsPharmaceutical PreparationsPoly(A)-Binding ProteinsProtein BiosynthesisProteinsPublic HealthRNA-Binding ProteinsRegulationResearchResistanceSeizuresSystemTechniquesTranslation InitiationTranslation ProcessTranslationsUntranslated RegionsViralVirus Diseasesautistic behaviourbiophysical techniquesinfluenza infectioninsightmRNA Expressionparalogous geneprogramsrecruit
项目摘要
Project Summary
Our research program focuses on the mechanism of eukaryotic protein synthesis and translational
control. The two projects we are currently studying are: (1) the mechanism of translational control by the fragile
X mental retardation protein (FMRP), and (2) the mechanism of translation initiation on influenza A virus (IAV)
mRNAs. Fragile X syndrome is a disease that afflicts about 100,000 Americans and about 3 million people
worldwide, resulting in intellectual disability, childhood seizures, and autistic behavior in the patients. The
disease is caused by the transcriptional silencing of the fragile X mental retardation 1 gene (FMR1). FMR1 gene
codes for an RNA-binding protein, FMRP, which is highly expressed in the brain and is essential for the normal
development of the brain. Mammals have two autosomal paralogs of FMRP designated as fragile X related 1
and 2 (FXR1 and FXR2) proteins. FMRP, FXR1 and FXR2 have been implicated in regulating the translation of
several mRNAs. However, the precise mechanism by which these proteins regulate the expression of these
mRNAs is unknown. The goal of the first project is to understand the molecular mechanism underlying the
regulation of protein synthesis by FMRP, FXR1 and FXR2. We will use a robust in vitro translation system,
biochemical techniques and quantitative biophysical methods to significantly advance our understanding of the
molecular mechanism used by FMRP, FXR1 and FXR2 to regulate protein synthesis. Results of these studies
will provide useful insights in identifying potential drug targets to treat fragile X syndrome.
The goal of the second project is to investigate the mechanism of translation initiation by IAV mRNAs.
IAV is responsible for several thousand deaths annually and is a severe threat to global public health. We have
new data that indicate that IAV mRNAs may use a non-canonical mechanism of translation initiation. Our studies
show that poly A binding protein 1 (PABP1) binds to the highly conserved sequences present in the 5’-UTR of
IAV mRNAs. Additionally, we show that the translation of the IAV mRNA is more resistant to the inactivation of
eukaryotic initiation factor 4E (eIF4E) compared to a control mRNA. We hypothesize that the recruitment of
PABP1 to the viral 5’-UTRs tethers eIF4G and promote the assembly of the translation initiation complex in an
eIF4E-independent manner. This may favor the translation of IAV mRNAs under cellular stress conditions in the
cell, which is known to reduce the activity of eIF4E. We will determine whether the binding of PABP1 to the 5’-
UTR of IAV mRNAs is essential for translation initiation and the viral cycle using in vitro techniques and cellular
IAV infection studies. Our research will lead to fundamental new knowledge about the process of translation
initiation on IAV mRNAs, which could help in the development of new antiviral drugs.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SIMPSON JOSEPH其他文献
SIMPSON JOSEPH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SIMPSON JOSEPH', 18)}}的其他基金
Mechanism of Protein Synthesis and Translational Control
蛋白质合成与翻译控制机制
- 批准号:
10581388 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Mechanism of Protein Synthesis and Translational Control
蛋白质合成与翻译控制机制
- 批准号:
10207047 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Mechanism of Protein Synthesis and Translational Control
蛋白质合成与翻译控制机制
- 批准号:
10631100 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Translational Control by the Fragile X Mental Retardation Protein
脆性 X 智力迟钝蛋白的翻译控制
- 批准号:
9199419 - 财政年份:2016
- 资助金额:
$ 35.26万 - 项目类别:
Interaction of Influenza A virus NS1 protein with PABP1 and eIF4G
甲型流感病毒 NS1 蛋白与 PABP1 和 eIF4G 的相互作用
- 批准号:
9243088 - 财政年份:2016
- 资助金额:
$ 35.26万 - 项目类别:
Molecular Role of 16S Ribosomal RNA in Translocation
16S 核糖体 RNA 在易位中的分子作用
- 批准号:
6462889 - 财政年份:2002
- 资助金额:
$ 35.26万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 35.26万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 35.26万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 35.26万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 35.26万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 35.26万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 35.26万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 35.26万 - 项目类别: